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Abstract
Background: The progress of electronic health technologies and biobanks holds enormous promise for efficient
research. Evidence shows that studies based on sharing and secondary use of data/samples have the potential to
significantly advance medical knowledge. However, sharing of such resources for international collaboration is
hampered by the lack of clarity about ethical and legal requirements for transfer of data and samples across
international borders.
Main text: Here, the International Clinical Trial Center Network (ICN) reports the legal and ethical requirements
governing data and sample exchange (DSE) across four continents. The most recurring requirement is ethical
approval, whereas only in specific conditions approval of national health authorities is required. Informed consent is
not required in all sharing situations. However, waiver of informed consent is only allowed in certain countries/
regions and under certain circumstances. The current legal and ethical landscape appears to be very complex and
under constant evolution. Regulations differ between countries/regions and are often incomplete, leading to
uncertainty.
Conclusion: With this work, ICN illuminates the unmet need for a single international collaborative framework to
facilitate DSE. Harmonising requirements for global DSE will reduce inefficiency and waste in research. There are
many challenges to realising this ambitious vision, including inconsistent terminology and definitions, and
heterogeneous and dynamic legal constraints. Here, we identify areas of agreement and significant difference as a
necessary first step towards facilitating international collaboration. We propose the establishment of a working
group to continue the comparison across jurisdictions, create a standardised glossary and define a set of basic
principles and fundamental requirements for DSE.
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Background
Over recent years, topics like “big data”, “biobanks” and
“data sharing” have gained momentum in the health science
community. The widespread adoption of electronic health
records has raised the interest of researchers in exchanging
clinical data for secondary use [1]. Patient data can be
merged on a large scale for epidemiological studies or dis-
ease monitoring [2, 3]. Besides health information technol-
ogy, biobanks of human specimens have a growing role in
the creation of actionable knowledge in health science [4, 5].
Over the last three decades, these repositories have evolved,
and the information associated with biological samples has
increased enormously [6]. Multiple international initiatives
are currently promoting collaboration between existing bio-
banks to enable larger research projects [7–10].
Despite the increasing opportunities for the advancement
of biomedical research through DSE and the availability of
data/sample to exchange, this promise has not yet been fully
realised through an actual increase in data and sample shar-
ing [11]. This mismatch may be explained by the obstacles
presented to researchers of having to navigate the regulatory
framework governing the sharing of data/samples. Inter-
national exchange can be particularly challenging due to
conflicting regulations and overlapping terminologies [2,
12]. Adding further complexity, regulations continue to
evolve. Some tools have been developed to support re-
searchers, but many cover a limited geographical region or
are not sufficiently mature or current [2, 13–15].
Legal restrictions are not the only barriers to seamless
DSE. Among others, further limiting factors may be the
reluctance of investigators who are aiming to publish first,
as well as the interests of research funders. However, we
believe that a clearer regulatory landscape would help to
overcome also this hindrance to fully enable robust, ideally
patient-controlled DSE [16]. In this article, the International
Clinical Trial Center Network (ICN) [17], a network that
brings together top-tier experience and knowledge of 19
clinical trial centres from across the globe, draws a simpli-
fied picture of the regulatory requirements to exchange
health data and biospecimens across four continents and
highlights differences that could influence the conduct of
international projects. The ICN brings together different
non-profit institutions with the common objective to en-
courage continuous international dialogue, to provide guid-
ance to researchers, and to promote international
collaboration. Relevant terms concerning data protection
are also compared. This work should help to advance the
global exchange of data and samples as well as to support
the development of a valuable tool that helps researchers in
large-scale international research projects.
Main text
We surveyed members of the ICN between July 2018
and October 2019, collecting detailed information on
local guidelines, regulations and restrictions concerning
the international exchange of data and samples, centred
on 3 out of the 4 key dimensions of health information
exchange defined by Holmgren and colleagues [18].
1. What defines the “Rules” of Exchange?
We collected information on policies applying in the
context of international DSE and authorities involved in
its approval.
2. Who is exchanging? Relationship between
exchanging partners
Special requirements/restrictions concerning data/
samples receivers (e.g. specific countries or for-profit
organizations) were assessed.
3. What is exchanged? Types of information
Here, we focused specifically on the further use for re-
search purposes of already available clinical data/samples
rather than the collection of new data/samples, distin-
guishing between: a) genetic data, non-genetic data and
biological samples; b) different data formats; and c) dif-
ferent levels of subject’s privacy protection. The present
report is not concerned with data format.
Thirteen centres from eleven countries contributed to
data gathering (ISO 3166 code in brackets): Austria
(AUT), China (CHN), United Kingdom (GBR), Italy
(ITA), Japan (JPN), Singapore (SGP), Sweden (SWE),
Switzerland (CHE), Turkey (TUR), Uganda (UGA) and
United States of America (USA). Hong Kong (HKG) and
Taiwan (TWN) are described as separate regions since
they have local regulations governing the international
transfer of data/samples that differ from Mainland
China. The regulatory requirements collected for the
United Kingdom are applicable for England, Northern
Ireland, Scotland and Wales. However, different health
authorities may be involved in the approval of specific
research projects. For each participating ICN country/re-
gion, a matrix showing the applicable requirements in
specific sharing situations was created. Differences
between the regulatory frameworks of represented coun-
tries/regions were identified and are reported in this
article, together with differences in the terms related to
data protection.
The regulatory framework is in continuous evolution
For all participating countries/regions, this article pro-
vides a cross-sectional appraisal of the current situation,
recognising continuous evolution that requires frequent
revision. In some countries/regions, a number of regula-
tory aspects are not currently precisely defined. At the
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time of writing, a certain degree of regulatory uncer-
tainty also affects the European Union (EU). On 25th
May 2018, the General Data Protection Regulation
(GDPR) was enforced within EU. The GDPR creates
new exemptions for research and leaves some room to
member states to specify their own rules [19]. In re-
sponse, many EU member states are reviewing national
regulations governing data protection in the field of clin-
ical research, addressing areas in which flexibility is per-
mitted by the GDPR.
According to the GDPR, personal data may only be
transferred to third countries if an adequate level of data
protection within the meaning of Art. Forty-five is guar-
anteed in the receiving country or if the data transfer is
subject to an exception pursuant to Art. 49. Thirteen ad-
equacy decisions have been adopted so far, as reported
on the website of the European Commission. Of the
countries/regions participating in this project, only
Japan, Switzerland, and the USA (limited to the Privacy
Shield framework) have been recognized as providing
adequate protection.
Data protection terminology is not consistent across
countries/regions
In all participating countries/regions, information which
may be used to identify a specific person indirectly is
also considered personal data. However, in Japan and
Singapore, coded information can be regarded as non-
personal information where the access to the original
personal information is unlikely or prevented. Interest-
ingly, the Japanese definition specifically distinguishes
between different personal information recording forms
(documents, drawings or electromagnetic records). The
latter includes electronic, magnetic and other recording
forms not otherwise specified that cannot be recognized
directly through the human senses. In Singapore, all data
pertaining to an individual, whether true or false, is con-
sidered personal data. In Hong Kong, Japan and the
United Kingdom, deceased persons do not have personal
data. This also applies to China and Taiwan, although
not directly specified in the local definition of personal
data. According to recital 27 of the GDPR, deceased per-
sons do have personal data. However, the regulation
only protects living persons. This leaves member states
the possibility to regulate the processing of personal data
of deceased persons. Austria and Sweden do not provide
for special provisions in this regard. In Italy, the rights
described in articles 15 to 22 of the GDPR for deceased
persons can be exercised by those who have an interest,
or act to protect the data subject or for family reasons
deserving protection [20]. In Switzerland, deceased per-
sons’ data fall under the doctor-patient confidentiality
agreement, but is not considered personal data. Special
regulations apply for research with deceased persons, i.e.
surrogate consent can be provided by the ethics commit-
tee [21]. In the other countries, the respective data pro-
tection regulations apply in respect of deceased
individuals, but this is limited to 10 years in Singapore
and 50 years in the USA [22, 23].
Only the European countries, Singapore and Taiwan
could provide a legal definition for the term “pseudony-
mization” or “coding”. In these countries/regions, pseu-
donymized (coded) data can no longer be attributed to a
specific subject without the use of additional informa-
tion. Only Singapore distinguishes between reversible
and irreversible coding. In the latter case, original values
are properly disposed of and the pseudonymisation is
done in a non-repeatable fashion. In Mainland China,
the term “de-identification” is used when pseudonyms,
encryption, hash functions or other technical methods
are used to replace identifiers [24]. In the USA, data are
considered de-identified if they have been stripped of
common identifiers and there is no reasonable basis to
believe that the information can be used to identify an
individual [25]. Hong Kong, Taiwan and Uganda do not
have a single, pervasive legal definition for data which
cannot be traced to a specific person, whereas the Euro-
pean countries, China, Singapore and Turkey prefer the
term “anonymized”. However, some definitions differ in
how strictly the possibility of re-identification is limited.
While GDPR and Swiss law set a relatively low bar for
“identifiable”, anonymized data should be impossible to
link with an individual according to the Turkish law. In
all cases, anonymized data are not considered as
personal data, nor are de-identified data in the USA.
The Japanese Data Protection Law distinguishes three
categories of information: personal information, an-
onymously processed information and non-personal
information [26]. Under other laws such as the GDPR,
anonymously processed information and non-personal
information correspond to pseudonymized information
and anonymized information, respectively.
The only countries/regions having a legal definition
for the term “encrypted” are Singapore, Taiwan and the
United Kingdom. In the United Kingdom and Singapore,
encrypted data are considered as personal data. In
Taiwan, encryption is the process of making personal
data irreversibly unidentifiable. In other countries/re-
gions, this would probably be considered as anonymiza-
tion. Of note, Taiwan does not have a definition for the
term “anonymized”.
A list of definitions is provided in the supplementary
information (see Additional file 1).
Data privacy level affects transferability
As shown in Table 1, following the respective country-
specific regulations it is possible to transfer data/samples
with any privacy protection level from Austria, Switzerland,
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Mainland China, United Kingdom, Hong Kong, Japan,
Sweden, Taiwan and USA [19, 21, 27–36]. In the other
countries/regions, including Italy as the only European rep-
resentative, the transfer of data/samples containing directly
identifiable information (i.e. uncoded data/samples) is not
permitted [20, 22, 37–40]. According to the Turkish Data
Protection Law, uncoded data/samples can be transferred
with participants’ consent [41]. However, regulations on
clinical research and personal health data state that personal
data must be coded or anonymized for privacy [38, 42, 43].
Informed consent may not be always required
As shown in Table 2, informed consent is always required
to transfer any data/samples for research from Mainland
China, Italy and Singapore. This also applies to Japan, al-
though the requirements for biological samples are not fully
defined yet. In Turkey, Hong Kong, Taiwan, USA and the
European countries except Italy, informed consent is not re-
quired to transfer anonymized data. In these same countries,
except for Austria, informed consent is not required for the
transfer of anonymized biological samples either. However,
in Switzerland and Turkey, the patient has to be informed
about the planned anonymization of biological samples and
has the right to refuse (opt-out consent) [21].
In Uganda, Switzerland and the United Kingdom, waiver
of informed consent is permitted by Ethic Committee and
applicable regulatory authority in situations where it is prob-
lematic or challenging to obtain consent or where the public
interest of research outweigh the interests of the subjects
[21, 37, 44, 45]. In the United Kingdom, an additional ap-
proval from a health authority is required in these cases
[44]. In Sweden, research may be carried out without
informed consent if weakened state of health prevents the
subject from expressing an opinion. There is to be consult-
ation with the patient’s closest relatives and a custodian or
other legal representative. However, proxy consent is not
required, as only the research subject (if > 18 years old) can
give consent in this country [46].
National health authorities are involved less often than
ethics committees
A comparison of the required approvals is displayed in
Table 3. In countries/regions where informed consent is not
required to transfer anonymized data/samples, approval
from the ethics committee is not required either, except for
Turkey. In this country, ethical approval but no informed
consent is required to transfer anonymized data/samples. In
the United Kingdom, ethical approval is only required to
transfer coded and uncoded data/samples for specific re-
search projects. This also applies to Switzerland where, fur-
thermore, approval is only required if the Swiss institution
transferring the data/samples is involved in the project. The
creation of databases and biobanks does not require ap-
proval in neither of the two countries just mentioned [21,
47]. However, British researchers have the option to seek a
five-years lasting generic ethical approval for a range of re-
search within the conditions of the ethical approval [47]. In
all other countries, ethical approval is always required to
transfer coded and uncoded data/samples.
In Austria, Hong Kong, Italy, Japan, Singapore and the
USA, no national health authority is involved in the inter-
national transfer of data/samples for research purposes. In
contrast, Uganda, Taiwan and Turkey require the approval
of the local health authority (Uganda National Council for
Table 1 Transferability of data/samples with different level of subject’s privacy protection
AUT CHE CHN GBR HKG JPN ITA SGP SWE TUR TWN UGA USA
Transferability
Uncoded data/sample yes yes yesa yes yes yesb no no yes no yes no yes
Coded data/sample yes yes yesa,b yes yes yesb yes yes yes yes yes yes n.a
Anonymized data/sample yes yes yesa yes yes yesb yes yes yes yes yes yes yesb
n.a “not applicable”, this type of data/samples is not defined in the law
aThe cross-border transfer of non-genetic data is not regulated but the transfer is possible
bDifferent terms from coded/anonymized are used to categorize subject’s privacy protection (see above)
Table 2 Requirements for informed consent (IC) to transfer data/samples abroad
AUT CHE CHN GBR HKG JPN ITA SGP SWE TUR TWN UGA USA
IC required to transfer
Uncoded data/samples yes yes yes yesb yes yesd,e n.a. n.a. yesb n.a. yes n.a. yes
Coded data/samples yes yesb yese yesb yes yesd,e yes yes yesb yes yes yesb n.a.
Anonymized data/samples yesa noc yes no no yesd,e yes yes no noc no yesb noe
n.a “not applicable”, this type of data/samples is not transferable or is not defined in the law
aBiological samples only
bWaiver of IC allowed under certain conditions
cPatient has to be informed about the planned anonymization of biological samples and has the right to refuse
dNot regulated for biological samples
eDifferent terms from coded/anonymized are used to categorize subject’s privacy protection (see above)
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Science and Technology, the Ministry of Health and Wel-
fare and Ministry of Health, respectively) in all sharing situ-
ations [37, 43, 48]. In the remaining countries/regions,
health authorities are only involved in certain types of
transfer.
Conclusions
The heterogeneous nature and complexity of several dis-
eases and the deep characterization of individuals have led
to the rapid development of personalized medicine. Access
to large amount of health data is the next challenge for this
medical model [49]. Where the available data in one country
may not be sufficient to efficiently develop new
pharmacogenetic-based treatment strategies and new algo-
rithms to diagnose patients, DSE represents a huge resource
to gain validity of findings and increase the impact of re-
search. However, the lack of a unified ethical and legal
environment presents an obstacle for the scientific commu-
nity [2, 12]. The present work demonstrates that researchers
currently operate within a very complex legal and ethical
landscape. Regulations differ between countries/regions and
are often incomplete, leading to uncertainty. Differences can
also be found between regulations within a single country.
In Turkey for example, although the data protection law al-
lows the usage of uncoded data with subjects’ consent, sub-
regulations restrict the usage of uncoded data relating to
health. In addition, the rapid evolution of regulations over
time make it impractical for researchers to keep abreast of
the latest regulations across all jurisdictions. There is an un-
met need for an accessible resource that provides informa-
tion on country-specific requirements for DSE. Despite this,
the complexity of this field means that in many cases, re-
searchers may still require the guidance of experienced pro-
fessionals [12]. This might be facilitated by International
networks of research institutions such as ICN.
The most universal requirement for transferring data
or samples across national borders identified in this
work is ethical approval, whereas approval of national
health authorities is required only in specific settings. In-
formed consent is not required in all sharing situations.
However, waiver of informed consent is only allowed in
certain countries/regions and under certain conditions.
When considering individuals’ privacy, the transfer of
solely anonymized data may seem to be a practical solu-
tion. However, anonymization terminates the ability to
link records with new datasets or to re-contact partici-
pants. Further, some argue that complete anonymization
is impossible as long as the original records still exist [2,
50], leading to concerns over potential data misuse and
compromised privacy. This work shows that transfer of
anonymized data may also not be subject to less strin-
gent regulation.
The ideal would be a single unified global legal and
ethical framework to which all countries/regions could
subscribe and that would permit seamless data and sam-
ple exchange. Sets of ethical principles for medical re-
search already exist, such as the Declaration of Helsinki,
the Declaration of Taipei, the Council for International
Organizations of Medical Sciences (CIOMS) inter-
national ethical guidelines for biomedical research in-
volving human subjects and the Organization for
Economic Co-operation and Development (OECD)
Guidelines on human biobanks and genetic research
databases. However, these are not legally binding instru-
ments under international law. Discordances can also be
found between these internationally recognized guide-
lines. Given the heterogeneous regulatory and legal land-
scape reported here, and disagreement even in simple
terminology and definitions, much work is needed in
order to achieve the above-mentioned goal of a unified
framework.
Table 3 Required approvals to transfer data/samples abroad
AUT CHE CHN GBR HKG JPN ITA SGP SWE TUR TWN UGA USA
Ethical approval required
Uncoded data/samples yes yesa,b yes yesa yes yesf n.a. n.a. yes n.a. yes n.a. yes
Coded data/samples yes yesa,b yesf yesa yes yesf yes yes yes yes yes yes n.a
Anonymized data/samples yese no yes no no yesf yes yes no yes no yes no
Approval from national health
authority required
Uncoded data/samples no noc yesd yesa no nof no n.a. yese n.a. yes n.a. no
Coded data/samples no noc yesd,f yesa no nof no no yese yes yes yes n.a
Anonymized data/samples no noc yesd yesa no nof no no no yes yes yes no
n.a “not applicable”, this type of data/samples is not transferrable or is not defined in the law
aWhen transferred for specific research projects. Not for creating databases or biobanks
bApproval is only required if the institution transferring the data/samples is involved in the project
cUnless data/samples are transferred to a country without adequate protection
dBiological samples and genetic data only
eBiological samples only
fDifferent terms from coded/anonymized are used to categorize subject’s privacy protection (see above)
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To address the need of global harmonization, we
propose a collaborative and interdisciplinary approach
trough the establishment of a working group including
researchers, patient representatives, information technol-
ogy experts and legal expertise from different geograph-
ical regions. This will require engagement of all relevant
stakeholders. The first step will be a further detailed de-
scription of the current regulatory landscape, ideally
with representation from all regions. This will allow gen-
eration of a library of shared and differing terms, identi-
fying areas in greatest need of harmonization. It has
become clear through this work that all regions share a
desire to adequately protect the rights of the individual
in DSE, and that the differences outlined in this manu-
script lie in interpretation of data protection and the
way in which it is defined. A key step will be agreeing a
glossary of standardized terms and definitions. Next,
guidance on the principles of responsible data and sam-
ple exchange should be agreed and published, allowing
governments and regulators to benchmark and
harmonize national regulations and laws. Finding the
balance between a subject’s right to privacy and the pub-
lic interest in advancing medical research in a manner
that would be widely acceptable will be challenging, as
already anticipated by the existing conflicts between
current requirements to deposit data in research reposi-
tories and the GDPR [51]. The work of other groups
such as the Global Initiative for the Ethical Use of Hu-
man Specimens (GIFT), who elaborated a set of recom-
mendations for standardizing informed consent, should
also be taken into consideration during this phase [52].
We recognise that harmonization of DSE will not in it-
self solve the limited extent of DSE. Even when DSE is
possible, whether sharing takes place depends on many
other factors including the attitudes of the investigators,
the interests or requirements of research funders and
others. However, we believe that a clearer regulatory
landscape would help to overcome also this hindrance to
fully enable robust, ideally patient-controlled health
data/sample usage [16].
Our report is the first to compare the requirements for
DSE across multiple jurisdictions spanning four conti-
nents and is strengthened by its representativeness. How-
ever, there are important limitations, including the lack of
representation from South America and Australasia. Fur-
thermore, a comprehensive and in-depth review of all
legal considerations for each jurisdiction is beyond the
scope of this preliminary survey. Data were provided by
relevant ICN members, which represent leading clinical
trials centres within the represented jurisdictions. We
consulted with legal experts but have not sought input
and verification from individual regulators. Additionally,
an official English translation of the national regulations
does not always exist. There is a need for further detailed
work in collaboration with regulators where possible, but
we consider the present overview a crucial first step to-
wards identifying obstacles and opportunities from DSE.
While we cannot directly mandate change, we hope that
this work can form the basis for progress through increas-
ing awareness, standardization and guidelines.
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